LYL273 for Patients With Relapsed or Refractory mCRC
LYL273 for Patients With Relapsed or Refractory mCRC
Recruiting · NCT05319314 · Registry updated 2026-06-09Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| LYL273 for Patients With Relapsed or Refractory mCRC | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, colonic disorder, colorectal cancer, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, neoplasm, rectal disorder | Recruiting | Phase 1 / Phase 2 | 2026-06-09 | NCT05319314 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Lyell Immunopharma, Inc. | 3 |
4 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| City of Hope Comprehensive Cancer Center | Duarte | United States | 263 |
| Dana-Farber Cancer Institute | Boston | United States | 1 |
| University of California San Francisco Medical Center | San Francisco | United States | 10 |
| University of Colorado Hospital - Anschutz Cancer Pavilion | Aurora | United States | 13 |